Earnings Releases·Nov 4, 2026, 4:05 PM ET

Cytokinetics — Third Quarter 2026 Earnings Summary

Total revenues surged to $47.6 million in Q3 2026 from $1.9 million in the prior-year period, driven by $44.5 million in net product revenue from MYQORZO, while the net loss narrowed to $190.1 million ($1.37 per share) from $306.2 million ($2.55 per share) in Q3 2025.
The company reaffirmed full-year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million and expects to submit a Supplemental NDA for aficamten in non-obstructive HCM in the U.S. in Q4 2026, with a UK launch also targeted for Q4 2026.
MYQORZO has achieved significant commercial traction with nearly 1,100 unique prescribers and over 2,800 patients dispensed year-to-date, supported by positive Phase 3 ACACIA-HCM results for non-obstructive HCM and regulatory approvals in the U.S., EU, UK, China, and Canada.
Cash and investments decreased to $1.6 billion as of September 30, 2026, from $1.7 billion in June 2026, while the company advanced multiple clinical programs including the completion of the CAMELLIA-HCM main treatment period in Japan and the AMBER-HFpEF Cohort 1 enrollment.